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Abstract  
Postpartum (or puerperal) psychosis (PP) is a severe psychiatric condition associated with 
hallucinations, delusions, cognitive disorganisation and mood problems, which affects 
approximately 1-2 out of every 1000 mothers shortly after childbirth. Whilst the risk factors 
for, and co-morbidities of, PP are relatively well-defined, currently the pathophysiology 
underlying the disorder is very poorly-specified. Here, I argue, on the basis of multiple lines 
of new evidence, that altered expression of the Cellular Communication Network (CCN) 
factor proteins (and of the heterodimerising CCN2 and CCN3 proteins in particular), may be 
associated with, and possibly causal for, increased PP risk. Future preclinical and clinical 
studies should aim to test this hypothesis as empirical support for it would provide much-
needed clues regarding the biological substrates of PP, and could point to predictive 
biomarkers for the condition.   
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Postpartum psychosis: an introduction 
Postpartum (or puerperal) psychosis (PP) is a severe psychiatric condition affecting 
approximately 1-2 of every 1000 new mothers (1). The disorder is characterised by multiple 
symptoms occuring shortly after childbirth, often within the first few days; these can include 
hallucinations, delusions (often related to the baby), cognitive disorganisation, and mood 
abnormalities including mania, depressive episodes and extreme anxiety (2). PP can severely 
impact upon mother-child bonding and family dynamics, and is a leading cause of maternal 
death via suicide, and infanticide (3). Treatments for PP are relatively effective in many cases 
if administered promptly, and include a combination of antipsychotic, mood-stabilising and 
sedative/anxiolytic drugs, and psychosocial support (2). However, some drugs lack efficacy, 
or exhibit unwanted side-effects, in some patients, and there are risks with administering 
some pharmacological treatments prophylactically during pregnancy due to teratogenicity 
issues (4). Thus, there remains a need for alternative treatments to be developed, which will, 
in turn, require an understanding of PP pathophysiology.  
Our current understanding of PP molecular pathophysiology is extremely poor for a 
number of reasons, including the inaccessibility of the human brain, the low prevalence and 
high symptom heterogeneity of the condition, and a historic lack of relevant animal models 
(5). Clinical studies have tended to focus upon obvious candidate biological systems in the 
perinatal period, including variations in steroid hormone levels, immune system fluctuations, 
and genes influencing the dopaminergic, serotonergic and stress-response systems. Whilst 
there is some evidence for altered sensitivity to postpartum steroid hormone levels, immune 
system hyperactivation, and a nominally-increased frequency of specific genetic variants 
within serotonergic genes in patients with PP, results from clinical studies so far have been 
limited and inconsistent (5). The nature of PP limits our ability to perform robust, hypothesis-
free, large-scale biochemical and genetic analyses, including genome-wide analyses which are 
now beginning to bear fruit in helping us to understand the biological basis of other, more 
common, mood and psychotic illnesses (6); even with ongoing multi-national collaborative 
efforts, the sample sizes required to identify a reasonable proportion of genetic risk variants 
(and thereafter risk pathways) are unlikely to be achieved in the near future. Hence, for rare 
disorders such as PP, investigations of sensible candidate biological pathways may still be 
warranted.    
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Ideally, we would like to know during pregnancy, or even before pregnancy, which 
women are at increased risk of being affected by PP, so that they can be closely monitored 
and receive early intervention for maximum therapeutic benefit. Whilst we know that women 
with a previous history of PP, bipolar disorder or schizophrenia are at substantially increased 
risk of PP, approximately half of women who experience PP have no prior psychiatric history 
(7). Biological differences between women experiencing PP, and those who do not, could 
potentially represent predictive biomarkers for the condition.  
In this Perspective, I hypothesise, based upon several lines of converging preclinical 
and clinical evidence, that the expression of Cellular Communication Network (CCN) family 
member proteins may be disrupted in women at risk of PP, and that detailed analysis of this 
system in future studies could feasibly yield insights into the pathophysiology of PP and 
signpost predictive biomarkers. 
The Cellular Communication Network (CCN) factor gene family 
The CCN gene family comprises six members formerly known as cysteine-rich angiogenic 
inducer 61 (CYR61, now CCN1), connective tissue growth factor (CTGF/CCN2), 
nephroblastoma-overexpressed (NOV/CCN3), WNT1-inducible signalling pathway 1 
(WISP1/CCN4), WNT1-inducible signalling pathway 2 (WISP2/CCN5) and WNT1-inducible 
signalling pathway 3 (WISP3/CCN6). The family member proteins share a tetramodular 
domain and regulate a variety of developmental and physiological processes including cell 
adhesion, migration, proliferation, differentiation and survival (8). Although CCN proteins are 
expressed intracellularly, they appear to play a particularly important role within the 
extracellular matrix where they interact with multiple components, including a variety of cell 
membrane receptors (8); this site of action is pertinent as extracellular matrix proteins have 
been highlighted as candidate modulators of mood disorders (9). The CT domain shared 
across CCN members is a common motif in dimerising proteins (10), and there is evidence 
that CCN members such as CCN2 and CCN3 can form homo or heterodimers; these two 
proteins may exert opposing effects (11), and in the nervous system, this is exemplified by 
CCN2 and CCN3’s anti- and pro-myelination effects respectively (12-14). Below, I argue that 
six key features of the CCN family member proteins (and specifically CCN2 and CCN3), render 
them plausible biological mediators of PP risk.     
5 
 
1. Altered gene expression in animal models displaying abnormal maternal 
behaviour 
It should initially be acknowledged that complex psychiatric conditions such as 
psychosis are challenging to model accurately or comprehensively in animals (15). This caveat 
notwithstanding, recent work in three independent, and distinct, animal models 
demonstrating abnormal maternal behvaioural phenotypes has indicated correlated CCN2 
and CCN3 brain gene expression changes.  
In a pharmacological mouse model, the steroid sulfatase (STS) enzyme was acutely 
inhibited in new mothers to mimic postpartum steroid sulfatase deficiency which is 
associated with increased postpartum psychopathology risk (16) (including potentially 
increased postpartum psychosis risk (17)) in women. Mouse mothers in which STS was acutely 
inhibited exhibited apparently normal dam-pup interactions, but altered anxiety-related 
behaviours and a reduced startle response; the specific pattern of anxiety-related behaviours 
implicated an underlying genetic substrate within a small region of chromosome 15 (18). 
Expression screening of the 17 genes within this interval identified CCN3 as the only 
significantly differentially expressed (upregulated) gene in the brain between vehicle and 
inhibitor-treated mothers, and follow-up analyses of other CCN family members 
demonstrated significant brain overexpression of CCN2 and CCN4 genes in the latter group 
(18). 
In a genetic mouse model, the postpartum behaviour of wildtype mothers bearing 
transgenic pups over-expressing the imprinted gene Phlda2 was compared to that of wildtype 
mothers bearing wildtype pups (19). After birth, wildtype dams exposed in utero to transgenic 
offspring exhibited decreased nursing and grooming of pups, and an increased focus on nest 
building, relative to wildtype mothers exposed to wildtype pups. Analysis of global gene 
expression in the hippocampus and hypothalamus of mothers bearing transgenic pups 
revealed several significant differences from that in mothers bearing wildtype pups, including 
substantial upregulation of hippocampal Ccn3 expression (>2.1-fold change)(19).   
In pigs, a small proportion of new mothers demonstrate aggression towards their 
offspring, in some cases killing one or all of the litter. The ‘infantidal sow’ was the first animal 
model proposed for PP, and exhibits some degree of face validity for the condition: the extent 
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of aggression is influenced by familial, hormonal, and environmental factors, is greater for 
first litters, and is associated with behavioural correlates such as anxiety and restlessness (20). 
A preliminary analysis employing RNA sequencing to compare hypothalamic gene expression 
in infanticidal and non-infanticidal sows revealed increased CCN2 (CTGF) expression (~1.3-
fold) in the former group as one of the top 10 largest expression differences (21). Genetic 
analysis of the pig model has also implicated PAX3 in postpartum aggression (22); the 
chromosomal translocation-derived fusion transcription factor PAX3-FKHR appears to act as 
a transcriptional activator at CCN3 (23).       
2. Location under a genetic linkage peak for PP 
A seminal genetic study in a population of women with bipolar disorder who 
developed PP identified a genome-wide significant linkage signal on chromosome 16p13, and 
a genome-wide suggestive linkage signal at 8q24 (24). The suggestive linkage signal spanned 
14cM, from 135.7-149.7cM; the CCN3 gene is located at 138cM, and as such could potentially 
fully, or partially, explain this signal.    
3. PP-relevant spatiotemporal gene expression patterns and influence on 
relevant behavioural phenotypes  
CCN genes are expressed in the developing and adult mammalian brain, with 
associated proteins apparently more highly expressed in neurons than in glia (25). Across 
species, the highest expression of CCN2 and CCN3 is seen in brain regions underpinning higher 
cognitive functions and emotionality, including the hippocampus (CA1 region), and frontal 
and temporal cortices (25-27); interestingly, these brain regions appear to be structurally 
distinct in women at risk of PP who develop the condition relative to those who don’t (28), 
whilst alterations in the structure and function of the CA1 region of the hippocampus are 
amongst the most replicated neuroimaging findings in individuals with psychotic and/or 
bipolar illness (29).  
A priori, one might expect the expression of candidate genes for PP to fluctuate within 
the mother’s brain between late pregnancy and into the postpartum period. Although 
information on the brain expression of CCN genes across these timepoints in humans is 
inevitably lacking, there is some evidence from rodents that maternal brain CCN expression 
does change in a spatiotemporally-specific manner from mid-late gestation and into the 
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postpartum period (30). Notably, CCN3 expression decreases in both the maternal neocortex 
and cerebellum across these timepoints, but increases significantly in the hypothalamus 
(Figure 1); CCN2 levels, in contrast, remain relatively stable across all four brain regions.         
If there is a true link between abnormal CCN family gene expression and PP, we might 
reasonably expect to see altered expression of these genes/proteins in tissue samples from 
individuals with psychotic illness. In a recent comparison of global gene expression in 
prefrontal parvalbumin cells from individuals with schizophrenia versus healthy controls, 
more than 800 transcripts were identified as being differentially expressed, with CCN3 being 
one of the top hits (>40% change in expression)(31). Second, an analysis of plasma analytes 
in individuals at high risk of developing psychosis has suggested that conversion may be 
mediated by CCN2 (CTGF)(32). Thirdly, CCN3 (NOV) is functionally related to genes in which 
mutations are disproportionately highly observed in schizophrenia cases relative to controls 
(33). Finally, the protein discoidin domain receptor 1 (DDR1) has been proposed as a receptor 
for CCN3 (34); DDR1 is involved in myelination processes in the brain (35), and there is robust 
evidence for an association between genetic variants around the DDR1 locus and psychotic 
illness, possibly mediated via white matter abnormalities (36-39). Conceivably therefore, any 
CCN3 effects on psychosis risk might be mediated via DDR1.  
In addition to effects on psychosis risk, perturbed expression of CCN2 and/or CCN3 
might impact upon mood symptoms and relevant personality traits. CCN2 (CTGF) has recently 
been implicated as a prodepressant molecule on the basis of human and animal model studies 
(40), whilst CCN3 hippocampal expression is decreased ~1.7-fold in the ‘chronic social defeat’ 
mouse model of depression (41). Consistent with the results from the STS enzyme inhibition 
study, brain-specific deletion of Ccn3 has an anxiolytic effect in mice (42). New findings from 
a large Mendelian Randomisation study have suggested that plasma CCN2 is significantly 
causally-associated with neuroticism and possibly also with depression (p=0.07), and that 
plasma CCN3 is significantly causally-associated with anxiety/panic attacks and agreeableness 
(43,44); in bipolar disorder, neurotic and (negative) agreeableness traits are reliable 
predictors of depressive and manic symptoms respectively (45).  
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Amongst some women with bipolar disorder, sleep deprivation appears to be a trigger 
for acute mood (manic) symptoms, and it is these individuals who appear to be at particularly 
high risk of developing PP (46). Emerging data hints that elevated blood CCN3 levels are 
associated with obstructive sleep apnea (OSA), a common condition associated with impaired 
sleep and subsequent cognitive processing, and with irritable or depressed mood (47). 
Feasibly, a predisposition to sleep disruption as a consequence of high CCN3 levels and 
heightened OSA risk, may play a role in vulnerability to PP. 
4. Expression regulated by pro- and anti-psychotic factors relevant to PP  
There is evidence from both in vivo and in vitro studies that exposure to pro- and anti-
psychotic factors can influence CCN family gene expression; however, many of these studies 
have focussed on tissues other than the brain, and the extent to which their results can be 
generalised to this tissue remains to be confirmed.    
Of relevance to the idea that a precipitous drop in maternal circulating steroid 
hormones (notably oestrogens) may somehow elicit psychosis in the postpartum period, work 
in rats has demonstrated that ovariectomy, and the associated decrease in circulating 
oestrogens, results in significantly decreased Ccn3 (Nov) expression in the hippocampus (48).    
Chronic stress results in up-regulation of the Ccn2 (Ctgf) gene in mouse hippocampus (49), 
whilst the administration of psychotomimetic or antipsychotic drugs results in increased CCN 
gene expression across the rodent brain (50,51). In the STS inhibition mouse model described 
above, the elevation in brain Ccn3 expression could be alleviated by concurrent adminstration 
of the clinically-efficacious antipsychotic ziprasidone (18), while in rats, oral administration of 
lithium (a mood-stabilising drug used to treat PP), is associated with substantial, and relatively 
specific, upregulation of Ccn3 kidney expression (52). In women with a history of bipolar 
disorder/psychosis, smoking appears to be associated with vulnerability to psychotic episodes 
during pregnancy and in the puerperium (53,54); in female mouse lung tissue, extended 
exposure to cigarette smoke has been associated with downregulation of CCNs 1,3 and 4 (55).  
Finally, in vitro studies have shown that CCN expression can be finely regulated by a 
diverse range of inflammatory mediators including cytokines (TNFα, IL1β, TGF-β), 
prostaglandins, nitric oxide, histamine, serotonin and extracellular matrix enzymes in a  
tissue-specific manner (56).      
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5. Role as a nexus between PP-relevant immune system and neuroanatomical 
measures  
Individuals with first-onset PP have been reported to show hyperactivation of the 
monocyte/macrophage arm of the immune system (57), possibly as a downstream 
consequence of changes in the abundance and/or activity of subsets of immunosuppressive 
regulatory T-cells (Tregs) (57,58). The proportion of circulating Tregs also appears to be 
abnormal (generally lowered) in individuals with bipolar disorder (59-61).   
Although little is currently known about the neuroanatomy of PP, pilot data indicates 
that individuals at high risk of PP exhibit abnormal myelination in the temporal lobe, and in 
sublobar areas (62), and one case of PP presented with white matter abnormalities within the 
splenium of the corpus callosum (63). Interestingly, in patients with bipolar disorder, the 
frequency of circulating Tregs correlates positively with markers of white matter integrity 
(64). Together these results suggest: a) that defective myelination processes may predispose 
to PP and associated conditions, and b) the possibility of a biological link between immune 
function and myelination processes across these conditions.  
Work by Dombrowki and colleagues has shown that CCN3 is secreted by Tregs, and 
mediates brain (re)myelination processes in mammals (12). On the basis of this finding, we 
have proposed that perturbations in the Treg-CCN3-(re)myelination axis may confer 
vulnerability to PP (65). The high expression of CCN3 in the temporal cortex, and adjacent 
structures, may potentially explain the myelination abnormalities seen here in patients with 
PP. Additionally, an in vitro study in mouse cortical neurons in which CCN3 was overexpressed 
showed impaired midline crossing of callosal projection neurons (66), providing a viable 
explanation for the corpus callosum structural abnormalities described in the PP case above.  
6. Putative role in conditions comorbid with PP 
Convergent findings from large general population, and disease-specific cohorts, 
support a robust association between the medical condition pre-eclampsia and postpartum 
psychiatric symptoms (67,68). Pre-eclampsia is a potentially life-threatening complication of 
late pregnancy, characterised by the onset of high blood pressure and proteinuria (69). Like 
PP, the pathophysiology of pre-eclampsia is poorly-understood, but abnormal placental 
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invasion and vascularisation processes are thought to be important (69); chronic maternal 
hypertension is a significant risk factor (69,70).      
Biological factors which have pleiotropic (independent) effects on both pre-eclampsia 
and PP risk may explain the observed link between the two conditions. Alternatively, these 
factors may solely (or predominantly) influence pre-eclampsia risk, and the development of 
this condition may then precipitate PP via mechanisms such as heightened perinatal stress or 
via adverse effects of hypertension on neural processes. CCN proteins, and CCN3 in particular, 
represent plausible pleiotropic biological risk factors.  
CCN family members influence angiogenesis across a variety of tissues, and in the 
placenta CCN1 and CCN3 are expressed in the endothelial cells of placental vessels with 
expression increasing throughout pregnancy (71); in the placenta, CCNs1-3 seem to act as 
regulators of trophoblast proliferation and migration, with CCN2 acting antagonistically (71). 
CCN1 and CCN3 levels are decreased in both the placental tissue and serum of mothers with 
early-onset pre-eclampsia, whereas CCN2 levels are increased in the serum of women with 
severe pre-eclampsia (71). In addition to a possible role in pre-eclampsia pathophysiology, 
CCN3 may play a role in affecting blood pressure more generally; the gene is very highly 
expressed in the zona glomerulosa of the adrenal gland, a tissue involved in the regulation of 
blood pressure via aldosterone secretion (72). Consistent with this, genomic studies have 
identified a genetic polymorphism within CCN3 (rs2071518) associated with blood pressure 
regulation (73), and plasma CCN3 is highly-significantly causally-linked to blood pressure 
(43,44).  
Given the well-established relationship between bipolar disorder and PP risk, one 
might expect CCN proteins to influence cellular processes relevant to both disorders. CCN3 is 
thought to regulate intracellular calcium levels (74), and aberrant calcium signalling has been 
implicated in both bipolar disorder (75) and PP (76) risk. Finally, CCN proteins can influence 
Notch and Wnt signalling cascades (10,71), the dysfunction of which has been reported in 
both bipolar disorder and schizophrenia (77,78) and in cases presenting with postpartum 
psychiatric symptoms (79). 
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Discussion 
Currently, the pathophysiology of PP is poorly-understood. The rarity and complexity 
of the condition precludes large case-control biochemical and genetic studies, and there is 
arguably a need to focus on candidate systems. Historically, however, candidate gene or 
system-led approaches have been associated with high rates of false positive and negative 
findings (80), though some of this poor reproducibility may be accounted for by the relatively 
arbitrary selection of candidates based upon limited and unreliable theory. Above, I have 
discussed why I believe the CCN family represents a strong candidate system warranting 
further investigation in PP; a putative pathophysiological model based upon these arguments 
is presented in Figure 2. Despite there being a strong relationship between a prior history of 
bipolar disorder and PP risk, to date, there is little evidence from genomic and physiological 
studies for abnormal CCN function in bipolar disorder; this ‘absence of evidence’ may be due 
to technical limitations, or alternatively, as CCN gene/protein levels fluctuate considerably 
throughout pregnancy and the postpartum period, it is plausible that it is specifically 
abnormalities in the expression/function of these proteins (against a background of bipolar 
disorder-associated pathophysiological changes) that confer PP risk. Additionally, it should be 
appreciated that whilst a link between CCN proteins and PP is explicitly discussed here, the 
functions/attributes of the CCN family mean that these proteins could also feasibly play a role 
in disorders with overlapping symptoms and biology, notably postpartum depression and 
anxiety.       
Future work may involve comparing the levels of CCN2 and CCN3 proteins (and their 
interactors) in peripheral tissues in individuals with PP, in individuals at risk of PP, and in 
healthy controls across pregnancy and the postpartum period, as well as comparing the 
sequences of these genes across groups. Parallel animal model studies, in which levels of 
CCN2 and CCN3 proteins are systematically varied and PP-relevant neurobiological and 
behavioural measures assessed, may be useful for indicating causality. 
Should the work above suggest that changes in the CCN family are associated with, or 
causal for, an increased risk of postpartum psychopathology, they could act as predictive 
biomarkers, and may be amenable to normalisation through therapeutic approaches 
currently under development (81).   
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Figure 1. Expression of CCN3 across four regions of C57BL/6J mouse brain from mid-late 
pregnancy (postconception day 16, PC16) to postpartum days 1 and 3 (PP1 and PP3). RNA 
sequencing data are taken from Ray  et al. (30) and expression is measured via Fragments of 
Kilobase per Transcript per Million mapped reads (FPKM) across three biological replicates 
per timepoint (mean and standard error of the mean shown for each timepoint).    
Figure 2. A putative pathophysiological model for how abnormal CCN family member 
expression may predispose to postpartum psychosis. 
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